Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers

Study acronym: PANGU-1
StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened
    • Study sites: 0 to 1
    • Collaborators expanded, about 6 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.
Trial Details
NCT Number NCT07864701
Lead Sponsor Chengdu Anticancer Bioscience, Ltd.
Collaborators: Peking University Cancer Hospital & Institute
Conditions
(from sponsor)		 Advance Solid Tumors, Lymphoma, Non-Hodgkin
Related terms Lymphoma, Non-Hodgkin
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov